Using 68Ga-ICAM-1pep PET/CT to assess cancer treatment response
68Ga-ICAM-1pep PET/CT Imaging of Tumor Responses to Radiotherapy in Cancer Patients
This study is testing a new imaging agent to see if it can help predict how well radiotherapy works for people with metastatic cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04596670 on ClinicalTrials.gov |
What this trial studies
This open-label study investigates the predictive value of 68Ga-ICAM-1pep in metastatic cancer patients undergoing radiotherapy. Participants will receive an intravenous injection of 68Ga-ICAM-1pep, and PET/CT imaging will be conducted before and after treatment to evaluate tumor responses. The study aims to identify ICAM-1 as a potential biomarker for predicting the abscopal effect of radiotherapy, which is currently not assessed in clinical practice. Visual and semiquantitative methods will be employed to analyze the imaging results.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-80 with suspected or confirmed lung, esophagus, cervical, or other cancers requiring PET/CT imaging.
Not a fit: Patients who are pregnant, nursing, or have severe hepatic or renal dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for predicting treatment responses in cancer patients undergoing radiotherapy.
How similar studies have performed: While the use of ICAM-1 as a biomarker is novel, preclinical studies have shown promising results in predicting radiotherapy effects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18-80 years old; 2. ECOG score 0 or 1 point; 3. Patients with suspected or confirmed lung cancer, esophagus cancer, cervical cancer or other cancers who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging. Exclusion Criteria: 1. Pregnant or nursing; 2. Severe hepatic or renal dysfunction; 3. Low WBC (less than 3 x 10\^9/L); 4. Unable to comply with the PET/CT imaging procedures.
Where this trial is running
Beijing, Beijing Municipality
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Hua Zhu, Ph.D — Peking University Cancer Hospital & Institute
- Study coordinator: Ting Zhang
- Email: zhangt0183@bjmu.edu.cn
- Phone: +8610-82802893
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.